"Investing in biotech is an art that requires fluency in both business and science,
as well as sophisticated translational skills to connect the two worlds." EcoR1 Capital
ERYTECH PHARMA 26.65 -2.74% Volume 43 952 Resistance 28 Support 26 Price Targets: from 29 to 70 EUR (Oddo) - 35 EUR (Gilbert Dupont)
NICOX 11.910 -1.98% Volume 165 804 Price Target 14 EUR (Invest Securities Source Cercle Finance)
SANOFI 88.07 -0.70% Volume 901 882 Short-Term Upward Trend Price Target: 93-95 EUR Invalidation point < 85.9 EUR
13/01/2017 Understanding the Behavior of CELYAD Stock
CELYAD 19.540 (c) +5.05% Volume 30 140
"Analyst says Celyad takes lead in CAR-T for solid tumors" FierceBiotech
04/01/2017 Understanding the Behavior of AB SCIENCE Stock
AB SCIENCE 17.09 +9.69% Volume 674 107 Only invest in biotech stocks with at least one near-term, value-driving news
03/01/2017 Understanding the Behavior of AB SCIENCE Stock
AB SCIENCE 15.70 +5.94% Volume 244 565 Variation 1 month +25.54% Fibonacci Retracements 38% & 50%
November & December 2016 - Understanding the Behavior of CELYAD Stock
CELYAD EDISON 2016
"Celyad has reported at the American Society of Haematology (ASH) conference that the last treated patient from the three patient 30m cell dose cohort had stable AML disease for 12 weeks after NRK-2 treatment."
"NKR-2 takes a lead positon in solid tumours"
"Valuation: Rebased and adjusted to €45 per share"
30/11/2016 - Understanding the Behavior of GENTICEL Variation 1 month +81.82%
GENTICEL franchit une étape déterminante de son partenariat avec Serum Institute concernant l'utilisation de GTL003 dans des vaccins multivalents. La Société a également obtenu un brevet américain protégeant Vaxiclase et GTL003 - GENTICEL successfully completes determining milestone in partnership with Serum Institute regarding use of GTL003 in multivalent vaccines. The Company has also been granted US patent protecting Vaxiclase and GTL003
25/11/2016 - Understanding the Behavior of ABIVAX 7.61 (c) +8.71% Volume 24 296 Variation 3 months + 89.30%
ABIVAX organise un déjeuner investisseurs avec des leaders d’opinion qui portera sur les nouvelles approches thérapeutiques pour lutter contre le VIH - ABIVAX to Host Key Opinion Leader Luncheon for Investors Focused on Novel Approaches to HIV Therapy November 28, 2016 in New York
23/11/2016 - 10:36 Understanding the Behavior of AB SCIENCE Stock 10.18 -0.20% Vol. 9 044
Pending Results from Phase III Trial of Masitinib in ALS: Q1 2017
22/11/2016 - Trading the Biotech News: CELLECTIS 16.80 (c) +0.90% Volume 74 068
22/11/2016 - Trading the Biotech News: INNATE PHARMA 14.65 (c) -0.75% Volume 451 528
21/11/2016 - Understanding the Behavior of CELYAD Stock - Stock up 6 d. in a row
THINK (THerapeutic Immunotherapy with NKR-2) is a multinational open-label Phase Ib study to assess the safety and clinical activity of multiple administrations of autologous NKR-2 T-cells in seven, refractory cancers including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma).
This trial will be conducted in the US and in Europe.
13/11/2016 - Understanding the Behavior of INNATE PHARMA Stock - November 7-13, 2016 Variation 5 days +20.31%
1. SITC 2016 - National Harbor, MD Nov 9-13, 2016 - Bristol-Myers Squibb, Inc., Innate Pharma SA, Marseille, France, and Ono Pharmaceutical Company Limited, Osaka, Japan
"The combination of lirilumab plus nivolumab has a similar safety profile to that observed with nivolumab monotherapy"
2. Two straight days of gains after Trump victory: 11/09 & 11/10, 2016
31/10/2016 Understanding the Behavior of CELLECTIS Stock - Cell Therapy: UCART19 Treatment: B Acute Lymphoblastic Leukemia Ph I 16.32 -0.61% Vol 19 551
30/10/2016 Understanding the Behavior of AB SCIENCE Stock - drug candidate: Masitinib - Treatment of ALS Four Steps (Chart Boursorama)
10/09/2016 - POXEL 7.78 (c) -5.81% Volume 204 654 Variation 5 days -4.07%
MACD is slightly above zero_RSI 49.8_Mid-Term Support 7.1
September 12, 2016 – Before market opens. 2016 June 30th, Financial Statement_Publication des résultats semestriels
Poxel to Present New Imeglimin and PXL770 Data at the 52nd European Association for the Study of Diabetes Annual Meeting
"Imeglimin Improves Vascular Dysfunction in Type 2 Diabetes Animal Models"
"PXL770, a Novel Direct AMPK Activator, Inhibits Hepatic de novo Lipogenesis for the Treatment of Metabolic Disorders"
"PXL770, a Novel Direct AMPK Activator, Improves Metabolic Disorders in Diet Induced Mice Model of Obesity and Diabetes"
09/07/2016 1.10 pm - SANOFI 69.70 -0.54% Volume 573 042 MACD <0 above signal line_ RSI 42
Pull Back toward 65-62 EUR?
09/07/2016 12 am - BONE THERAPEUTICS 12.850 -3.56% Volume 7 258 MACD < 0 below signal line_RSI 12 oversold in Low Volume
Identification of key support?